The primary publication from the COG trial has been published today, with OCTRU Lead Statistician, Susan Dutton heading up the publication. The study concluded that the use of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not improve the overall survival, but has palliative benefits in a subgroup of these difficult-to-treat patients with short life expectancy. Future research should focus on identification of predictive biomarkers to identify this subgroup of benefiting patients.
Click here to access the publication